KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Total Liabilities: 2009-2025

Historic Total Liabilities for Ionis Pharmaceuticals (IONS) over the last 16 years, with Sep 2025 value amounting to $2.4 billion.

  • Ionis Pharmaceuticals' Total Liabilities fell 0.14% to $2.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 billion, marking a year-over-year decrease of 0.14%. This contributed to the annual value of $2.4 billion for FY2024, which is 7.22% down from last year.
  • Latest data reveals that Ionis Pharmaceuticals reported Total Liabilities of $2.4 billion as of Q3 2025, which was up 2.62% from $2.4 billion recorded in Q2 2025.
  • In the past 5 years, Ionis Pharmaceuticals' Total Liabilities ranged from a high of $2.6 billion in Q3 2023 and a low of $1.6 billion during Q1 2021.
  • For the 3-year period, Ionis Pharmaceuticals' Total Liabilities averaged around $2.5 billion, with its median value being $2.4 billion (2024).
  • In the last 5 years, Ionis Pharmaceuticals' Total Liabilities soared by 43.28% in 2023 and then dropped by 7.63% in 2024.
  • Ionis Pharmaceuticals' Total Liabilities (Quarterly) stood at $1.8 billion in 2021, then increased by 6.58% to $2.0 billion in 2022, then skyrocketed by 32.76% to $2.6 billion in 2023, then declined by 7.22% to $2.4 billion in 2024, then declined by 0.14% to $2.4 billion in 2025.
  • Its Total Liabilities stands at $2.4 billion for Q3 2025, versus $2.4 billion for Q2 2025 and $2.3 billion for Q1 2025.